BACKGROUND AND AIMS: β-thalassemia major patients are susceptible to Hepatitis C Virus (HCV) infection owing to life-long dependency for blood-transfusion. Moreover, this patient population is at risk of progression of liver fibrosis or development of cirrhosis as a consequence of both iron overload and HCV infection. Hence, this study was carried out to evaluate efficacy and safety of the combination regimen of sofosbuvir and daclatasvir for HCV infection in β-thalassemia major patients. METHODS: The present study was a prospective observational study which enrolled multi-transfused β-thalassemia major patients treated with a combination regimen of sofosbuvir (400 mg) and daclatasvir (60 mg) daily for 12 weeks for HCV infection during May 2016 and November 2016 depending upon inclusion and exclusion criteria of the study. Sustained virological response at post-treatment week-12 (SVR-12) was defined as negative HCV-RNA at week-12 after completion of antiviral treatment. RESULTS: A total of 10 multi-transfused patients with β-thalassemia major were included in the study. Average age of the patient was 13.60 ± 4.38 years. All the included patients were treatment-naïve, non-cirrhotic and infected with HCV genotype-3. All the patients achieved SVR-12. There was significant reduction in aspartate aminotransferase (p = 0.005) and alanine aminotransferase level (p = 0.005) and serum ferritin level (p = 0.028) after completion of the antiviral treatment. The reported adverse events include nausea, vomiting and anorexia which were managed conservatively. None of the patient required dose reduction or termination of antiviral treatment. CONCLUSION: The study reports safety and efficacy of sofosbuvir-based treatment in non-cirrhotic, treatment-naive β-thalassemia major patients infected with HCV genotype-3. However, further studies with larger patient populations are needed to build up stronger evidence of safety and efficacy of this treatment approach for HCV infection in thalassemic patients.
BACKGROUND AND AIMS: β-thalassemia major patients are susceptible to Hepatitis C Virus (HCV) infection owing to life-long dependency for blood-transfusion. Moreover, this patient population is at risk of progression of liver fibrosis or development of cirrhosis as a consequence of both iron overload and HCV infection. Hence, this study was carried out to evaluate efficacy and safety of the combination regimen of sofosbuvir and daclatasvir for HCV infection in β-thalassemia major patients. METHODS: The present study was a prospective observational study which enrolled multi-transfused β-thalassemia major patients treated with a combination regimen of sofosbuvir (400 mg) and daclatasvir (60 mg) daily for 12 weeks for HCV infection during May 2016 and November 2016 depending upon inclusion and exclusion criteria of the study. Sustained virological response at post-treatment week-12 (SVR-12) was defined as negative HCV-RNA at week-12 after completion of antiviral treatment. RESULTS: A total of 10 multi-transfused patients with β-thalassemia major were included in the study. Average age of the patient was 13.60 ± 4.38 years. All the included patients were treatment-naïve, non-cirrhotic and infected with HCV genotype-3. All the patients achieved SVR-12. There was significant reduction in aspartate aminotransferase (p = 0.005) and alanine aminotransferase level (p = 0.005) and serum ferritin level (p = 0.028) after completion of the antiviral treatment. The reported adverse events include nausea, vomiting and anorexia which were managed conservatively. None of the patient required dose reduction or termination of antiviral treatment. CONCLUSION: The study reports safety and efficacy of sofosbuvir-based treatment in non-cirrhotic, treatment-naive β-thalassemia major patients infected with HCV genotype-3. However, further studies with larger patient populations are needed to build up stronger evidence of safety and efficacy of this treatment approach for HCV infection in thalassemic patients.
Entities:
Keywords:
DAA, Direct Acting Antiviral; DCV, Daclatasvir; ETR, End of Treatment Response; HCV, Hepatitis C Virus; PegINF-α, Pegylated Interferon-α; RBV, Ribavirin; RVR, Rapid Virological Response; SOF, Sofosbuvir; SVR12, Sustained Virological Response Post-treatment Week-12; direct acting antivirals; hemoglobinopathies; viral hepatitis
Authors: Vito Di Marco; Marcello Capra; Emanuele Angelucci; Caterina Borgna-Pignatti; Paul Telfer; Paul Harmatz; Antonis Kattamis; Luciano Prossamariti; Aldo Filosa; Deborah Rund; Maria Rita Gamberini; Paolo Cianciulli; Marianne De Montalembert; Francesco Gagliardotto; Graham Foster; Jean Didier Grangè; Filippo Cassarà; Angela Iacono; Maria Domenica Cappellini; Gary M Brittenham; Daniele Prati; Antonello Pietrangelo; Antonio Craxì; Aurelio Maggio Journal: Blood Date: 2010-06-15 Impact factor: 22.113
Authors: Vito Di Marco; Marcello Capra; Francesco Gagliardotto; Zelia Borsellino; Daniela Cabibi; Francesco Barbaria; Donatella Ferraro; Liana Cuccia; Giovanni Battista Ruffo; Fabrizio Bronte; Rosa Di Stefano; Piero L Almasio; Antonio Craxì Journal: Haematologica Date: 2008-06-12 Impact factor: 9.941
Authors: Elise J Smolders; Anouk M E Jansen; Peter G J Ter Horst; Jürgen Rockstroh; David J Back; David M Burger Journal: Clin Pharmacokinet Date: 2019-10 Impact factor: 6.447
Authors: Reham M Dawood; Ahmed A Gomaa; Mai Abd El Meguid; Essam A Hassan; Ghada M Salum; Hany Mahmoud Fares; Mostafa K El Awady; Eman M Fares; Gamal Esmat Journal: Asian Pac J Cancer Prev Date: 2022-04-01